sub:assertion {
  d:DB05109 v:identifier "DB05109" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05109" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05109> ;
    dv:drugbank-id "DB05109" ;
    dv:x-atc <http://bio2rdf.org/atc:L01CX01> ;
    dv:x-cas <http://bio2rdf.org/cas:114899-77-3> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA165958349> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Trabectedin> ;
    dct:description "Trabectedin, also referred as ET-743 during its development, is a marine derived antitumoral agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas. The European Commission and the U.S. Food and Drug Administration (FDA) have granted orphan drug status to trabectedin for soft tissue sarcomas and ovarian cancer."@en ;
    dct:identifier "drugbank:DB05109" ;
    dct:title "Trabectedin"@en ;
    a dv:Drug ;
    rdfs:label "Trabectedin [drugbank:DB05109]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05109> .
}